#91
|
||||
|
||||
Âñå, êëþêâó ïðè ÈÌÂÏ çàáàíèëè!
Áîëüøå íå ÅÂÌ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#92
|
||||
|
||||
Vaccination Not a "License for Sex"
 ïðîøëîì ãîäó íà EUSUHM äîêëàä÷èêó áûë çàäàí âîïðîñ-óòâåðæäåíèå èç çàëà, ÷òî âàêöèíàöèÿ äåâî÷åê ïðîòèâ ÂÏ× ÿêîáû ïðîâîöèðóåò (èëè ìîæåò ïðîâîöèðîâàòü) ê áîëåå ðàííåìó íà÷àëó ïîëîâîé æèçíè. Ñêàçàííîå, ÷åñòíî ãîâîðÿ, îáåñêóðàæèëî (è íå òîëüêî ìåíÿ, à è ïðåäñåäàòåëÿ ), ïðè ýòîì ïîêàçàëîñü àáñóðäíûì. Òåïåðü âîò, îêàçûâàåòñÿ, ÷òî äàæå èññëåäîâàíèÿ ïðîâîäÿòñÿ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#93
|
||||
|
||||
Media Use by Children Younger Than 2 Years
Ìíå ïîêàçàëîñü äîñòàòî÷íî èíòåðåñíûì è ïîëåçíûì, íàáðåë äîñòàòî÷íî ñëó÷àéíî.
Èçâèíèòå, åñëè óæå áûëî, èëè âîîáùå îáùåèçâåñòíàÿ âåùü. POLICY STATEMENT FROM THE AMERICAN ACADEMY OF PEDIATRICS Media Use by Children Younger Than 2 Years [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#94
|
||||
|
||||
Öèòàòà:
òàêæå ìîæåò çàâèñåòü îò òîãî, êòî êàêèå îïóáëèêîâàííûå êëèí. òðàéëû âêëþ÷èë/âûêëþ÷èë âîò ïðåäûäóùàÿ èþëüñêàÿ ïóáëèêàöèÿ, ãäå ïîèñê áûë ïî íîÿáðü 2011 - âñåãî 10 ÐÊÈ, 3 èñêëþ÷åíî: Thirteen trials, including 1616 subjects, were identified for qualitative synthesis from 414 potentially relevant references; 10 of these trials, including a total of 1494 subjects, were further analyzed in quantitative synthesis. The random-effects pooled risk ratio (RR) for cranberry users vs nonusers was 0.62 (95% CI, 0.49-0.80), with a moderate degree of heterogeneity (I(2) = 43%) after the exclusion of 1 outlier study. On subgroup analysis, cranberry-containing products seemed to be more effective in several subgroups, including women with recurrent UTIs (RR, 0.53; 95% CI, 0.33-0.83) (I(2) = 0%), female populations (RR, 0.49; 95% CI, 0.34-0.73) (I(2) = 34%), children (RR, 0.33; 95% CI, 0.16-0.69) (I(2) = 0%), cranberry juice drinkers (RR, 0.47; 95% CI, 0.30-0.72) (I(2) = 2%), and subjects using cranberry-containing products more than twice daily (RR, 0.58; 95% CI, 0.40-0.84) (I(2) = 18%). Arch Intern Med. 2012 Jul 9;172(13):988-96. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. êîêýéíîâñêàÿ íà èþëü 2012 - 24 ÐÊÈ, 11 èñêëþ÷åíî: This updated review includes a total of 24 studies (six cross-over studies, 11 parallel group studies with two arms; five with three arms, and two studies with a factorial design) with a total of 4473 participants. Ten studies were included in the 2008 update, and 14 studies have been added to this update. Thirteen studies (2380 participants) evaluated only cranberry juice/concentrate; nine studies (1032 participants) evaluated only cranberry tablets/capsules; one study compared cranberry juice and tablets; and one study compared cranberry capsules and tablets. The comparison/control arms were placebo, no treatment, water, methenamine hippurate, antibiotics, or lactobacillus. Eleven studies were not included in the meta-analyses... èõ ðåçóëüòàòû: women with recurrent UTIs (RR 0.74, 95% CI 0.42 to 1.31);... children with recurrent UTI (RR 0.48, 95% CI 0.19 to 1.22); åñëè ñðàâíèòü äåòåé ñ ðåöèäèâèð. èíôåêöèåé - ïåðâûõ àíàëèç ïîêàçàë 3 êðàòíîå ïðåâîñõîäñòâî êëþêâû, âòîðîé - äâóêðàòíîå, íî óæå ñòàò. íåäîñòîâåðíîå.  îòñóòñòâèå áåçîïàñíûõ àëüòåðíàòèâ, ñòîèò ëè ïîëíîñòüþ ñáðàñûâàòü ñî ñ÷åòîâ òàêîå ëå÷åíèå, êîòîðîå â 2-3 ðàçà ñîêðàùàåò êîëè÷åñòâî ðåöèäèâîâ ó äåòåé?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#95
|
|||||
|
|||||
Òåðàïèÿ óïîðíîãî êàíäèäîçíîãî ìàñòèòà ó êîðìÿùèõ
Ïîäåëþñü, ïîêà ññûëêè â áðàóçåðå îòêðûòû.
...Êîëëåãà îáðàòèëàñü çà ñîâåòîì ïî ïîâîäó êîðìÿùåé æåíùèíû, ó êîòîðîé íåñêîëüêî ìåñÿöåâ ðåöèäèâèðóåò êàíäèäîçíûé ìàñòèò. Ïîêà êîðìèëèöà ìàæåò ñîñêè êëîòðèìàçîëîâîé ìàçüþ - âñå ïðîõîäèò. Êàê òîëüêî ïåðåñòàåò - âñå âîçâðàùàåòñÿ. Âîçíèê ðåçîííûé âîïðîñ - à ìîæíî ëè íàçíà÷èòü êëîòðèìàçîë âíóòðü? Ðåáåíîê íà ÃÂ, åìó ïîëòîðà ãîäà. ÐËÑ ãîâîðèò óâåðåííîå "íåò". Öèòàòà:
Òî åñòü î÷åðåäíîé ïîâîä äëÿ ðîññèéñêîãî ïåäèàòðà ïðåðâàòü ÃÂ. À âîò drugs.com íå ñîãëàñåí: Öèòàòà:
ïåðåâîä: Öèòàòà:
...Åùå ïîíðàâèëñÿ èíòåðåñíûé êåéç ðåïîðò, â êîòîðîì ñîâðåìåííûå ïîäõîäû ê ðåöèäèâèðóþùåìó êàíäèäîçíîìó ñòîìàòèòó ïðîïèñàíû ìàêñèìàëüíî ÷åòêî: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
Öèòàòà:
Âîçìîæíî, êîëëåãàì-ïåäèàòðàì ïðèãîäèòñÿ.
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#96
|
||||
|
||||
Ïîëåçíûé ðåñóðñ äëÿ ðîäèòåëåé (ìîæíî ðåêîìåíäîâàòü àíãëîÿçà÷íûì ìàìàì-ïî÷åìó÷êàì):
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#97
|
||||
|
||||
Âîò êàêîé ñèìïàòè÷íûé ãàéäèê ïîïàëñÿ, ïî èñïîëüçîâàíèþ íåáóëàéçåðà.
Recommandations for best practice of nebulisation B. Dautzenberg, M.H. Becquemin, J.P. Chaumuzeau, P. Diot, for the GAT (Groupe Aerosol Therapy) [1] Recommendations issued by the Groupe AérosolThérapie (GAT) of the Société de Pneumologie de Langue Française (SPLF), November 2006 Tirés à part : B. Dautzenberg [2] Hôpital Pitié-Salpêtrière, Service de Pneumologie et Réanimation, 47, boulevard de l’Hôpital, 75651 Paris cedex 13 Ñîõðàíþ, ÷òîá íå ïîòåðÿòü: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Êîðîòêî è ïî äåëó. Ýòî â äîïîëíåíèå ê ñòàòüå äëÿ ðîäèòåëåé: http://forums.rusmedserv.com/showpos...89&postcount=3
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#98
|
||||
|
||||
Íîâûé ãàéäëàéí ïî ëå÷åíèþ îñòðûõ ñðåäíèõ îòèòîâ îò Àìåðèêàíñêîé Àêàäåìèè Ïåäèàòðèè
Ïðóôëèíê:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïåðåâîä: Àìåðèêàíñêàÿ àêàäåìèÿ ïåäèàòðèè (ÀÀÏ) îïóáëèêîâàëà îáíîâëåííîå êëèíè÷åñêîå ðóêîâîäñòâî ïî äèàãíîñòèêå è ëå÷åíèþ íåîñëîæíåííîãî îñòðîãî ñðåäíåãî îòèòà (ÎÑÎ) ó äåòåé â âîçðàñòå îò 6 ìåñÿöåâ äî 12 ëåò. Íîâûé ãàéäëàéí ïðåäîñòàâëÿåò áîëåå ñòðîãèå äèàãíîñòè÷åñêèå êðèòåðèè, äëÿ ñíèæåíèÿ ÷àñòîòû íåîáîñíîâàííîãî íàçíà÷åíèÿ àíòèáèîòèêîâ; îí áûë îïóáëèêîâàí 25 ôåâðàëÿ 2013ã íà ñàéòå ÀÀÏ, è âûéäåò â ïå÷àòü â ìàðòîâñêîì íîìåðå æóðíàëà Pediatrics. Îáíîâëåííàÿ âåðñèÿ êëèíè÷åñêîãî ðóêîâîäñòâà îñíîâûâàåòñÿ íà ïðåäûäóùåì ãàéäëàéíå 2004 ãîäà âûïóñêà, à òàêæå íà âñåîáúåìëþùåì îáçîðå ëèòåðàòóðû, ïðîâåäåííîì â 2009 ãîäó ãðóïïîé âåäóùèõ ìåäèöèíñêèõ ýêñïåðòîâ.  çàâèñèìîñòè îò âîçðàñòà ïàöèåíòà è òÿæåñòè ñèìïòîìîâ, ÎÑÎ ìîæåò òðåáîâàòü èëè íåìåäëåííîãî íàçíà÷åíèÿ àíòèáèîòèêîâ è àíàëüãåòèêîâ, èëè âðåìåííîãî íàáëþäåíèÿ è îòñðî÷êè ìåäèêàìåíòîçíîé òåðàïèè. Ãàéäëàéí îïèñûâàåò îñíîâíûå ïîäõîäû ê òåðàïèè áîëè, âàðèàíòû àíòèáèîòèêîòåðàïèè, ïðîôèëàêòèêó ÎÑÎ è òàêòèêó ïðè ðåöèäèâèðóþùèõ ÎÑÎ. Íåêîòîðûå ïîëîæåíèÿ èç íîâîãî ðóêîâîäñòâà * Äèàãíîç ÎÑÎ äîëæåí îñíîâûâàòüñÿ íà íàëè÷èè óìåðåííîé èëè âûðàæåííîé ñòåïåíè âûáóõàíèÿ áàðàáàííîé ïåðåïîíêè (ÁÏ); èëè âïåðâûå âîçíèêøåé îòîðåè (èñêëþ÷àÿ ñëó÷àè íàðóæíîãî îòèòà ñ îòîðååé). Äèàãíîç ÎÑÎ ìîæåò áûòü âûñòàâëåí ïðè ëåãêîì âûáóõàíèè ÁÏ è íàëè÷èè áîëè â óõå - íå ðàíåå, ÷åì ÷åðåç 48 ÷àñîâ îò íà÷àëà ñèìïòîìîâ; èëè â ñî÷åòàíèè ñ èíòåíñèâíîé ãèïåðåìèåé ÁÏ. Ó ðåáåíêà, íå ñïîñîáíîãî ãîâîðèòü î ñâîèõ æàëîáàõ ñëåäóåò îðèåíòèðîâàòüñÿ íà ãðèìàñó áîëè ïðè ïîäåðãèâàíèè óøíîé ðàêîâèíû èëè íàäàâëèâàíèè íà íàðóæíîå óõî. * Äèàãíîç ÎÑÎ íå äîëæåí áûòü âûñòàâëåí ó ðåáåíêà, åñëè ïíåâìàòè÷åñêàÿ îòîñêîïèÿ è/èëè òèìïàíîìåòðèÿ íå ïîäòâåðæäàþò íàëè÷èå âûïîòà â ñðåäíåì óõå. * Ëå÷åíèå ÎÑÎ ñêëàäûâàåòñÿ èç áîëåóòîëÿþùåé è ýòèîòðîïíîé òåðàïèè. Àíòèáèîòèêè ñëåäóåò íàçíà÷àòü â ñëó÷àå äâóñòîðîííåãî èëè îäíîñòîðîííåãî ÎÑÎ ó äåòåé â âîçðàñòå ìåíåå 6 ìåñÿöåâ, ñ âûðàæåííûìè ñèìïòîìàìè (óìåðåííîé èëè ñèëüíîé îòàëãèåé, èëè îòàëãèåé ïðîäîëæèòåëüíîñòüþ áîëåå 48 ÷àñîâ, èëè ëèõîðàäêîé âûøå 39° C) è ñèìïòîìàìè ñðåäíåé òÿæåñòè, à òàêæå ïðè äâóñòîðîííåì ÎÑÎ ó äåòåé â âîçðàñòå îò 6 äî 23 ìåñÿöåâ. * Íà îñíîâàíèè ïðèíÿòèÿ ñîâìåñòíîãî ñ ðîäèòåëÿìè ðåøåíèÿ, â ñëó÷àÿõ îäíîñòîðîííåãî, ñðåäíåé ñòåïåíè òÿæåñòè ÎÑÎ ó äåòåé â âîçðàñòå îò 6 äî 23 ìåñÿöåâ; èëè ñðåäíåé òÿæåñòè ÎÑÎ ó äåòåé áîëåå ñòàðøåãî âîçðàñòà - ìîæåò áûòü ïðåäëîæåíî êàê íåìåäëåííîå íàçíà÷åíèå àíòèáèîòèêîâ, òàê è îòêëàäûâàíèå àíòèáèîòèêîòåðàïèè, íàáëþäåíèå ðîäñòâåííèêàìè çà äèíàìèêîé ñèìïòîìîâ, è ïîâòîðíûé îñìîòð ïåäèàòðà - â áëèæàéøèå äíè; è åñëè ó ðåáåíêà â òå÷åíèå îò 48 äî 72 ÷àñîâ íåò çàìåòíîãî óëó÷øåíèÿ ñèìïòîìîâ, èëè ñèìïòîìû íàðàñòàþò - îäíîçíà÷íî òðåáóåòñÿ íàçíà÷åíèå àíòèáèîòèêîòåðàïèè. * Àìîêñèöèëëèí ÿâëÿåòñÿ àíòèáèîòèêîì ïåðâîãî âûáîðà, åñëè ðåáåíîê ïîëó÷àë åãî â ïîñëåäíèé ðàç áîëåå 30 äíåé íàçàä, íå èìååò îäíîâðåìåííî ãíîéíîãî êîíúþíêòèâèòà, èëè àëëåðãèè íà ïåíèöèëëèíû.  ïðîòèâíîì ñëó÷àå âðà÷è äîëæíû íàçíà÷àòü àíòèáèîòèêè, ãðóïïû ïåíèöèëëèíîâ - çàùèùåííûå îò β-ëàêòàìàç, èëè àíòèáèîòèêè èíûõ ãðóïï. * Ëå÷àùèé âðà÷ îáÿçàí ðåêîìåíäîâàòü ïàöèåíòó ïîâòîðíûé îñìîòð, â ñëó÷àå, åñëè ñèìïòîìû îòèòà óñèëèëèñü èëè íå èçìåíèëèñü â ïåðâûå 48 - 72 ÷àñà ïðèåìà íàçíà÷åííîãî âðà÷îì àíòèáèîòèêà; è èçìåíèòü íàçíà÷åííóþ òåðàïèþ, ñîîòâåòñòâåííî äàííûì íîâîãî îñìîòðà. * Ó äåòåé ñ ðåöèäèâèðóþùèì ÎÑÎ, äëÿ ñíèæåíèÿ ÷àñòîòû ðåöèäèâîâ ìîæåò áûòü ðåêîìåíäîâàíî ââåäåíèå òèìïàíîñòîìè÷åñêîé òðóáêè; ïðîôèëàêòè÷åñêîå íàçíà÷åíèå àíòèáèîòèêîâ áîëåå íå ñ÷èòàåòñÿ (!) ýôôåêòèâíîé ìåðîé ñíèæåíèÿ ÷àñòîòû ðåöèäèâîâ ÎÑÎ. * Âðà÷è äîëæíû ðåêîìåíäîâàòü ñòðîãîå ñîáëþäåíèå ãðàôèêîâ âàêöèíàöèè ïðîòèâ ïíåâìîêîêêîâîé èíôåêöèè è ïðîòèâ ãðèïïà, òàê êàê ýòî îñíîâíûå âàêöèíû, ïðåäîòâðàùàþùèå ÎÑÎ ó äåòåé. * Êëèíèöèñòû äîëæíû ïîääåðæèâàòü ïîëíîå è èñêëþ÷èòåëüíîå ãðóäíîå âñêàðìëèâàíèå â òå÷åíèå, êàê ìèíèìóì, ïåðâûõ 6 ìåñÿöåâ, òàê êàê ýòî äîñòîâåðíî ñíèæàåò ðèñê ÎÑÎ ó äåòåé ïåðâûõ ëåò æèçíè. * ÀÀÏ ïîääåðæèâàåò ìàêñèìàëüíîå ðàñïðîñòðàíåíèå ýòîãî êëèíè÷åñêîãî ðóêîâîäñòâà ñðåäè âñåõ ïðàêòèêóþùèõ âðà÷åé. Îçíàêîìèòüñÿ ñ ïîëíûì òåêñòîì ãàéäëàéíà ìîæíî íà îôèöèàëüíîì ñàéòå American Academy of Pediatrics [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Èëè â ïðèëîæåííîì ôàéëå.
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#99
|
|||
|
|||
Íàáðåë ñëó÷àéíî. Ìîæåò êîìó-òî áóäåò ïîëåçíûì (íà àíãëèéñêîì ÿçûêå).
Èçâèíèòå, åñëè óæå áûëî, èëè âîîáùå îáùåèçâåñòíàÿ âåùü. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Íåñêîëüêî ðóññêîÿçû÷íûõ ññûëîê: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - Êàê ñîâëàäàòü ñ ïëà÷åì Âàøåãî ðåáåíêà. - Ïîäãîòîâêà ê ðîæäåíèþ ðåáåíêà. - Êîãäà ñëåäóåò âûçûâàòü äåòñêîãî âðà÷à? - Âàø íîâîðîæäåííûé ðåáåíîê. Ñ óâàæåíèåì, Ôåäèé Áîãäàí Íèêîëàåâè÷. |
#100
|
|||
|
|||
Ãàéä Åâðîïåéñêîãî îáùåñòâà äåòñêîé ãàñòðîýíòåðîëîãèè, ãåïàòîëîãèè è ïèòàíèÿ ïî äèàãíîñòèêå è ëå÷åíèþ àëëåðãèè íà áåëîê êîðîâüåãî ìîëîêà ó äåòåé, îïóáëèêîâàííûé â æóðíàëå Journal of Pediatric Gastroenterology and Nutrition, àâãóñò 2012.
Abstract OBJECTIVES: This guideline provides recommendations for the diagnosis and management of suspected cow's-milk protein allergy (CMPA) in Europe. It presents a practical approach with a diagnostic algorithm and is based on recently published evidence-based guidelines on CMPA. DIAGNOSIS: If CMPA is suspected by history and examination, then strict allergen avoidance is initiated. In certain circumstances (eg, a clear history of immediate symptoms, a life-threatening reaction with a positive test for CMP-specific IgE), the diagnosis can be made without a milk challenge. In all other circumstances, a controlled oral food challenge (open or blind) under medical supervision is required to confirm or exclude the diagnosis of CMPA. TREATMENT: In breast-fed infants, the mother should start a strict CMP-free diet. Non-breast-fed infants with confirmed CMPA should receive an extensively hydrolyzed protein-based formula with proven efficacy in appropriate clinical trials; amino acids-based formulae are reserved for certain situations. Soy protein formula, if tolerated, is an option beyond 6 months of age. Nutritional counseling and regular monitoring of growth are mandatory in all age groups requiring CMP exclusion. REEVALUATION: Patients should be reevaluated every 6 to 12 months to assess whether they have developed tolerance to CMP. This is achieved in >75% by 3 years of age and >90% by 6 years of age. Inappropriate or overly long dietary eliminations should be avoided. Such restrictions may impair the quality of life of both child and family, induce improper growth, and incur unnecessary health care costs. |
#101
|
|||
|
|||
Role of Antidiarrhoeal Drugs as Adjunctive Therapies for Acute Diarrhoea in Children
Acute diarrhoea is a leading cause of child mortality in developing countries. Principal pathogens include Escherichia coli, rotaviruses, and noroviruses. 90% of diarrhoeal deaths are attributable to inadequate sanitation. Acute diarrhoea is the second leading cause of overall childhood mortality and accounts for 18% of deaths among children under five. In 2004 an estimated 1.5 million children died from diarrhoea, with 80% of deaths occurring before the age of two. Treatment goals are to prevent dehydration and nutritional damage and to reduce duration and severity of diarrhoeal episodes. The recommended therapeutic regimen is to provide oral rehydration solutions (ORS) and to continue feeding. Although ORS effectively mitigates dehydration, it has no effect on the duration, severity, or frequency of diarrhoeal episodes. Adjuvant therapy with micronutrients, probiotics, or antidiarrhoeal agents may thus be useful. The WHO recommends the use of zinc tablets in association with ORS. The ESPGHAN/ESPID treatment guidelines consider the use of racecadotril, diosmectite, or probiotics as possible adjunctive therapy to ORS. Only racecadotril and diosmectite reduce stool output, but no treatment has yet been shown to reduce hospitalisation rate or mortality. Appropriate management with validated treatments may help reduce the health and economic burden of acute diarrhoea in children worldwide.
Ññûëêà íà ñòàòüþ: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#102
|
|||
|
|||
Ñâåæûé ãàéä AAP ïî áàêòåðèàëüíûì ñèíóñèòàì
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#103
|
||||
|
||||
"Çäåñü ñïîðÿò ïîðîòü íå ïîðîòü, à ìíå êàýòñÿ âûõîä îäèí":
Primary Care Interventions to Prevent Child Maltreatment 2013 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] "Ìíå òàê êàýòñÿ". (Ñ, À.È. Ðàéêèí). |
#104
|
||||
|
||||
Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#105
|
||||
|
||||
NICE 2013 Feverish illness in children: assessment and initial management in children younger than 5 years
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |